Antibiotic-resistant bacteria might have a weakness: a unique sugar molecule on their surfaces. Targeting this sugar can make the bacteria easier for our immune system to attack, as new research in mice suggests.
If this method proves effective in humans, it could offer a new strategy to combat superbugs like Acinetobacter baumannii, Helicobacter pylori, and Campylobacter jejuni. Researchers from a recent study published in Nature Chemical Biology are optimistic about this breakthrough.
Ethan Goddard-Borger, a co-author of the study, highlights the need to create antibodies that can work safely in humans. The goal is to modify the mouse antibodies or find human equivalents that are just as effective.
Antibiotic-resistant bacteria are a global threat, particularly Gram-negative ones. These bacteria have tough outer layers that make them hard to treat. They often use a “sugar coat” to hide from our immune system, mimicking sugars found on human cells. This disguise helps them resist treatment.
Past research identified a sugar called pseudaminic acid (Pse), found only on the bacteria’s surface. Unlike sugars on human cells, Pse could be a promising target for treatment. By marking these bacteria as foreign, it helps the immune system recognize and attack them.
However, earlier studies faced challenges in extracting enough Pse to study effectively. The recent study tackled this by creating Pse molecules in the lab. They then developed special proteins called monoclonal antibodies to attach to these sugar molecules.
In lab tests, these antibodies worked well against the targeted bacteria. They successfully bound to Pse, even when the sugar structures varied.
The real test came in mice infected with A. baumannii. When the researchers tagged bacteria with antibodies, it made them visible to the immune system. Mice treated with the antibodies had a 100% survival rate over a week, while untreated mice did not survive past one day.
The researchers envision a future where these antibodies could help vulnerable hospital patients avoid infections. Since Pse is absent in human cells, this treatment might not harm healthy cells.
In the long run, the goal is to use these antibodies to develop vaccines for broad protection against Gram-negative bacteria. However, adapting these antibodies for human use is the next crucial step.
Brian Luna, an expert in microbiology at the University of Southern California, noted that while this approach shows promise, it has limitations. Many bacteria don’t express the same sugars. More research is needed to demonstrate broad effectiveness in clinical settings.
In summary, this research opens exciting possibilities in the fight against antibiotic-resistant infections, but extensive work remains before it becomes a practical treatment option.
For further insights into the science behind antibiotic resistance and the latest findings, you can check Nature Chemical Biology.
